Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor conferences.

• SVB Leerink 11th Annual Global Healthcare Conference, company presentation, Feb. 18, 2022, 9:20 a.m. ET
• Cowen 42nd Annual Health Care Conference, corporate panel discussion, Mar. 9, 2022, 12:50 p.m. ET

The sessions may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager TherapeuticsVoyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas.voyagertherapeutics.com    LinkedIn         Twitter

Investor Inquiries:        [email protected]

Media Inquiries:        Scott Santiamo[email protected]

You May Also Be Interested In

• Brewster Heights Orchard & Packing and Heritage Orchard Alliance Transaction Advances Following Agreement with Major Creditor
• Engine Technology Forum Praises House Energy and Commerce Committee for Passing Reauthorization of the Diesel Emissions Reduction Act
• MD Integrations Partners With LegitScript, Offering Telehealth Brands Expedited Path to Compliant Launch